Skip to main content
. Author manuscript; available in PMC: 2014 Feb 19.
Published in final edited form as: Mol Cancer Ther. 2012 Jul 23;11(10):2105–2115. doi: 10.1158/1535-7163.MCT-11-0873

Figure 2.

Figure 2

Combinatorial dose response to decitabine (5A2D) and romidepsin (Rom) in ccRCC and TNBC cell lines. (A) A498, (B) KIJ265T, (C) MDA-231, and (D) BT-20 cells were incubated with a dose of 0.1, 1, or 10μM decitabine for 48hrs. Romidepsin (0.5 to 7.5nM) was added in combination to the decitabine for a further 24hrs. Data is presented as proliferation curves with monotherapeutic controls included.